Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07207681 | Personalized KXV01 TCR Lentinvivo Injection as the Therapy for Advanced Solid Tumors | not yet recruiting | Phase 1 | 30 | The First Hospital of Jilin UniversityOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT06933524 | Evaluation of Safety and Tolerability of ATB-320 in Participants With Progressive or Metastatic Solid Tumors(ATB-320-001A) | not yet recruiting | Phase 1 | 24 | AutotelicbioINDUSTRY | 0 | Oct 1, 2025 |
| clinicaltrials |
| NCT07196579 | Personalized KXV01 TCR Lentinvivo Injection as the Therapy for Advanced Solid Tumors | not yet recruiting | Phase 1 | 30 | TCRx Therapeutics Co.LtdINDUSTRY | 1 | Sep 29, 2025 | clinicaltrials |
| NCT07170787 | A Study of IMM2510 + IMM01 Combination Therapy in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 104 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | Sep 12, 2025 | clinicaltrials |
| NCT07157956 | CVL006 Combination Therapy in Advanced Solid Tumors(CVL006-T1002) | not yet recruiting | Phase 1 / Phase 2 | 318 | Convalife (Shanghai) Co., Ltd.INDUSTRY | 1 | Sep 5, 2025 | clinicaltrials |
| NCT07142837 | Study of ZG005 in Combination With Gecacitinib and Chemotherapy for Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 153 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Aug 27, 2025 | clinicaltrials |
| NCT07136558 | Evaluation of ICP-B794 in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 410 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Aug 22, 2025 | clinicaltrials |
| NCT07110363 | A Clinical Study of BT02 in Treating Patients With Advanced Lung Cancer | not yet recruiting | Phase 1 | 58 | Biotroy TherapeuticsINDUSTRY | 0 | Aug 7, 2025 | clinicaltrials |
| NCT07107178 | A Clinical Study of BT02 for the Treatment of Patients With Advanced Malignant Melanoma | not yet recruiting | Phase 1 | 58 | Biotroy TherapeuticsINDUSTRY | 0 | Aug 6, 2025 | clinicaltrials |
| NCT07101549 | Treating Nectin-4-positive Advanced Solid Tumors With R-Star001 (Nectin-4-CART-IL18) | not yet recruiting | Phase 1 | 25 | changjianhuaOTHER | 1 | Aug 3, 2025 | clinicaltrials |
| NCT07088588 | Study of SYN608 for the Treatment of Advanced or Metastatic Solid Tumors | not yet recruiting | Phase 1 | 105 | Hangzhou SynRx Therapeutics Biomedical Technology Co., LtdINDUSTRY | 1 | Jul 28, 2025 | clinicaltrials |
| NCT07077252 | Phase I/II Study of SCTB39G in Advanced Solid Tumours | not yet recruiting | Phase 1 / Phase 2 | 30 | Sinocelltech Ltd.INDUSTRY | 1 | Jul 22, 2025 | clinicaltrials |
| NCT07061639 | A Study of QLS5133 Monotherapy in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 212 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 11, 2025 | clinicaltrials |
| NCT07057349 | CSB-321 Ph 1 in Immunotherapy for the Treatment of Cancer | not yet recruiting | Phase 1 | 40 | Cytosite Biopharma Inc.INDUSTRY | 1 | Jul 9, 2025 | clinicaltrials |
| NCT07049458 | Study of CHO-A04 in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 62 | Cho Pharma Inc.INDUSTRY | 1 | Jul 3, 2025 | clinicaltrials |
| NCT07030478 | A Study to Evaluate the Safety and Tolerability of EP0089 | not yet recruiting | Phase 1 / Phase 2 | 190 | Ellipses PharmaINDUSTRY | 0 | Jun 22, 2025 | clinicaltrials |
| NCT06998173 | Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DAT-1604 in Advanced Solid Tumor | not yet recruiting | Phase 1 | 228 | Danatlas Pharmaceuticals Co., LtdINDUSTRY | 1 | May 31, 2025 | clinicaltrials |
| NCT06991478 | SK-NK Injection in Patients With Advanced Solid Tumors Accompanied by Malignant Ascites | not yet recruiting | Phase 1 / Phase 2 | 10 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | May 28, 2025 | clinicaltrials |
| NCT06970132 | Study of SY-5933 Plus CT-707 in Advanced Solid Tumors With KRAS p.G12C Mutation | not yet recruiting | Phase 1 / Phase 2 | 102 | Shouyao Holdings (Beijing) Co. LTDOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT06966583 | NAD+ Supplement(NMN)With Radioimmunotherapy in Advanced NSCLC(NMN) | not yet recruiting | Phase 1 | 20 | Sichuan UniversityOTHER | 1 | May 12, 2025 | clinicaltrials |
| NCT06963398 | A Study of HS-10529 in KRAS G12D Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 520 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 0 | May 9, 2025 | clinicaltrials |
| NCT06963502 | A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 762 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 9, 2025 | clinicaltrials |
| NCT06956261 | NW-301 TCR-T in Patients With Advanced Solid Tumor | not yet recruiting | Phase 1 | 44 | Peking UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT06955390 | Clinical Trial of HRS-4642 Plus SHR-A2102 in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 32 | Henan Cancer HospitalOTHER_GOV | 1 | May 2, 2025 | clinicaltrials |
| NCT06949761 | A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of QLC1101 in Combination With Other Therapies in the Treatment of Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation | not yet recruiting | Phase 1 / Phase 2 | 240 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Apr 29, 2025 | clinicaltrials |
| NCT06947226 | A Clinical Study of 9MW2821 Monotherapy or Combined With Other Anticancer Therapy in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 188 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Apr 27, 2025 | clinicaltrials |
| NCT06932094 | Phase 1 Clinical Study of QLS5132 Monotherapy in Advanced Solid Tumors | not yet recruiting | Phase 1 | 256 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 23, 2025 | clinicaltrials |
| NCT06939270 | CD73/AXL Targeted HypoSti.CAR-T Cells in CD73/AXL Positive Advanced/Metastatic Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT06925659 | A Study of QLM2011 in Subjects With Advanced Solid Tumors | not yet recruiting | Phase 1 | 172 | Qilu Pharmaceutical (Hainan) Co., Ltd.INDUSTRY | 0 | Apr 17, 2025 | clinicaltrials |
| NCT06928363 | A First-in-human Study of KY-0301 in Patients With Advanced Solid Tumors. | not yet recruiting | Phase 1 / Phase 2 | 212 | Novatim Immune Therapeutics (Zhejiang) Co., Ltd.INDUSTRY | 0 | Apr 15, 2025 | clinicaltrials |
| NCT06885645 | First-In-Human Study in Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 | 30 | Chengdu Kanghong Biotech Co., Ltd.INDUSTRY | 0 | Apr 3, 2025 | clinicaltrials |
| NCT06906731 | A Study of SHR-9803 for Injection in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 27 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 2, 2025 | clinicaltrials |
| NCT06775236 | Clinical Trial of SYS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 410 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Mar 19, 2025 | clinicaltrials |
| NCT06872580 | A Study of QLS1209 in theTreatment of Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 149 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Mar 12, 2025 | clinicaltrials |
| NCT06787950 | Clinical Study of ASN-3186 in Patients with Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 200 | Jiangsu Yahong Meditech Co., Ltd aka AsierisINDUSTRY | 0 | Jan 22, 2025 | clinicaltrials |
| NCT06779045 | A Study of AK-1286 in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 50 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 0 | Jan 16, 2025 | clinicaltrials |
| NCT06755242 | A Study of GNC-077 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors | not yet recruiting | Phase 1 | 20 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 1, 2025 | clinicaltrials |
| NCT06752447 | A Phase I Study OfLNF2007 Monotherapy in Patients with Advanced Solid Tumors | not yet recruiting | Phase 1 | 94 | Shandong New Time Pharmaceutical Co., LTDINDUSTRY | 0 | Dec 30, 2024 | clinicaltrials |
| NCT05954091 | OH2 Administered by Intratumoral Injection | not yet recruiting | Phase 1 | 29 | Binhui Biopharmaceutical Co., Ltd.INDUSTRY | 0 | Dec 27, 2024 | clinicaltrials |
| NCT06652529 | Phase 1 Dose Escalation and Expansion to Evaluate AROG4-01 in Patients With Advanced Solid Tumors(AROG4-01-01) | not yet recruiting | Phase 1 | 35 | Aromics TherapeuticsINDUSTRY | 0 | Nov 7, 2024 | clinicaltrials |
| NCT06621615 | Clinical Study of CVL006 Injection in Advanced Solid Tumors | not yet recruiting | Phase 1 | 120 | Convalife (Shanghai) Co., Ltd.INDUSTRY | 0 | Oct 1, 2024 | clinicaltrials |
| NCT06614751 | A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway | not yet recruiting | Phase 1 | 112 | Danatlas Pharmaceuticals Co., LtdINDUSTRY | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06594874 | A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors | not yet recruiting | Phase 1 | 350 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06364501 | Phase 1 Trial of KH801 | not yet recruiting | Phase 1 | 17 | Beijing Kanghong Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 7, 2024 | clinicaltrials |
| NCT06531486 | A Study of XS-02 Capsules in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 96 | NovaOnco Therapeutics Co., Ltd.INDUSTRY | 0 | Aug 1, 2024 | clinicaltrials |
| NCT05474859 | Subjects With Advanced or Metastatic Solid Tumor Malignancies | not yet recruiting | Phase 1 | 30 | Xenthera, Inc.INDUSTRY | 0 | Jul 31, 2024 | clinicaltrials |
| NCT06528249 | Safety, Tolerability and Preliminary Efficacy of Erythrocyte-αPD-1 Conjugate in Patients With Advanced Malignancies | not yet recruiting | Phase 1 | 39 | Zhejiang Provincial People's HospitalOTHER | 0 | Jul 30, 2024 | clinicaltrials |
| NCT06383507 | A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors | not yet recruiting | Phase 1 | 18 | Zhejiang UniversityOTHER | 0 | Apr 25, 2024 | clinicaltrials |
| NCT06304818 | Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB14 in Adult Patients With Advanced Malignant Solid Tumours. | not yet recruiting | Phase 1 / Phase 2 | 515 | Sinocelltech Ltd.INDUSTRY | 0 | Mar 15, 2024 | clinicaltrials |
| NCT06277804 | A Phase I Study of LTC004 Combin With FC in Patients With Advanced/Metastatic Malignancies Tumor | not yet recruiting | Phase 1 | 48 | LetolabINDUSTRY | 0 | Feb 26, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Oct 6, 2025source: clinicaltrials